{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:16:11Z","timestamp":1792250171503,"version":"4.4.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.dmd.2026.100359","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T14:50:55Z","timestamp":1783090255000},"page":"100359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Microfluidic liver-chip to predict clinical drug-drug interaction net effects for precipitant drugs with dual CYP3A4 inhibition and induction potential"],"prefix":"10.1016","volume":"54","author":[{"given":"Lina","family":"Mettler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5385-0223","authenticated-orcid":false,"given":"Justine","family":"Bad\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Huth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Lohasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Alm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Streckfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1026-3985","authenticated-orcid":false,"given":"Hilmar","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5000-0581","authenticated-orcid":false,"given":"Peter","family":"Loskill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birk","family":"Poller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3244-002X","authenticated-orcid":false,"given":"Julia","family":"Riede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.dmd.2026.100359_bib1","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2165\/00003088-200342110-00003","article-title":"Factors affecting the clinical development of cytochrome p450 3A substrates","volume":"42","author":"Gibbs","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1124\/dmd.116.073411","article-title":"What can be learned from recent new drug applications? A systematic review of drug interaction data for drugs approved by the US FDA in 2015","volume":"45","author":"Yu","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s40495-017-0082-5","article-title":"Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a minireview illustrating recent developments and current opportunities","volume":"3","author":"Fowler","year":"2017","journal-title":"Curr Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.dmd.2026.100359_bib5","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1208\/s12248-013-9470-x","article-title":"Drug-drug interaction studies: regulatory guidance and an industry perspective","volume":"15","author":"Prueksaritanont","year":"2013","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.dmd.2026.100359_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.2174\/138920008784220664","article-title":"Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4","volume":"9","author":"Zhou","year":"2008","journal-title":"Curr Drug Metab"},{"issue":"6","key":"10.1016\/j.dmd.2026.100359_bib7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1124\/dmd.110.037523","article-title":"Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir","volume":"39","author":"Kirby","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100359_bib8","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40262-024-01350-x","article-title":"Time course of the interaction between oral short-term ritonavir therapy with three factor Xa inhibitors and the activity of CYP2D6, CYP2C19, and CYP3A4 in healthy volunteers","volume":"63","author":"Rohr","year":"2024","journal-title":"Clin Pharmacokinet"},{"issue":"21","key":"10.1016\/j.dmd.2026.100359_bib9","doi-asserted-by":"crossref","first-page":"6450","DOI":"10.1021\/bi00187a009","article-title":"Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site","volume":"33","author":"Shou","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.dmd.2026.100359_bib10","doi-asserted-by":"crossref","DOI":"10.1002\/cpph.9","article-title":"In vitro drug metabolism using liver microsomes","volume":"74","author":"Knights","year":"2016","journal-title":"Curr Protoc Pharmacol"},{"issue":"8","key":"10.1016\/j.dmd.2026.100359_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.dmd.2025.100117","article-title":"Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4\/5 inhibition potential of drugs","volume":"53","author":"Justine","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100359_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0928-0987(01)00135-X","article-title":"Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation","volume":"13","author":"LeCluyse","year":"2001","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.dmd.2026.100359_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.tiv.2019.05.019","article-title":"Validation of in vitro methods for human cytochrome P450 enzyme induction: outcome of a multi-laboratory study","volume":"60","author":"Bernasconi","year":"2019","journal-title":"Toxicol In Vitro"},{"issue":"8","key":"10.1016\/j.dmd.2026.100359_bib14","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1124\/dmd.107.018663","article-title":"A combined model for predicting CYP3A4 clinical net drug-drug interaction based on CYP3A4 inhibition, inactivation, and induction determined in vitro","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmd.2026.100359_bib15","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrd1851","article-title":"Predicting in vivo drug interactions from in vitro drug discovery data","volume":"4","author":"Wienkers","year":"2005","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib16","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.apsb.2016.04.004","article-title":"PBPK modeling and simulation in drug research and development","volume":"6","author":"Zhuang","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib17","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/ph14050429","article-title":"Cold-start problems in data-driven prediction of drug-drug interaction effects","volume":"14","author":"Dewulf","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"2","key":"10.1016\/j.dmd.2026.100359_bib18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/bib\/bbu010","article-title":"Toward more realistic drug-target interaction predictions","volume":"16","author":"Pahikkala","year":"2015","journal-title":"Brief Bioinform"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib19","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1124\/dmd.111.038968","article-title":"Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes","volume":"39","author":"Kotani","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3390\/biom14010099","article-title":"A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment","volume":"14","author":"Lee","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.dmd.2026.100359_bib21","series-title":"FDA Modernization Act 2.0. 117th Congress, 2nd session, S. 5002","year":"2022"},{"issue":"6","key":"10.1016\/j.dmd.2026.100359_bib22","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1021\/acsptsci.5c00162","article-title":"Modernizing preclinical drug development: the role of new approach methodologies","volume":"8","author":"Mehta","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100359_bib23","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/pharmaceutics15041300","article-title":"Microfluidic liver-on-a-chip for preclinical drug discovery","volume":"15","author":"Fu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/cpr.13099","article-title":"Liver microphysiological platforms for drug metabolism applications","volume":"54","author":"Kulsharova","year":"2021","journal-title":"Cell Prolif"},{"key":"10.1016\/j.dmd.2026.100359_bib25","article-title":"Liver-on-chips for drug discovery and development","volume":"27","author":"Mehta","year":"2024","journal-title":"Mater Today Bio"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib26","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/mi12050470","article-title":"A decade of organs-on-a-chip emulating human physiology at the microscale: a critical status report on progress in toxicology and pharmacology","volume":"12","author":"Rothbauer","year":"2021","journal-title":"Micromachines (Basel)"},{"issue":"6","key":"10.1016\/j.dmd.2026.100359_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1208\/s12248-023-00870-x","article-title":"A novel milli-fluidic liver tissue chip with continuous recirculation for predictive pharmacokinetics applications","volume":"25","author":"Rajan","year":"2023","journal-title":"AAPS J"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1124\/jpet.116.237495","article-title":"Quantitative assessment of population variability in hepatic drug metabolism using a perfused three-dimensional human liver microphysiological system","volume":"360","author":"Tsamandouras","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.dmd.2026.100359_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.785851","article-title":"A microphysiological cell-culturing system for pharmacokinetic drug exposure and high-resolution imaging of arrays of 3D microtissues","volume":"12","author":"Lohasz","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.dmd.2026.100359_bib30","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.dmd.2026.100359_bib31","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/dmd.106.012633","article-title":"Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions","volume":"35","author":"Obach","year":"2007","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100359_bib32","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejps.2011.04.008","article-title":"Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover","volume":"43","author":"Rowland Yeo","year":"2011","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"10.1016\/j.dmd.2026.100359_bib33","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/clpt.2013.170","article-title":"Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data","volume":"95","author":"Einolf","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100359_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/clpt.2013.187","article-title":"Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug","volume":"95","author":"Vieira","year":"2014","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.115.065581","article-title":"Evaluation of normalization methods to predict CYP3A4 induction in six fully characterized cryopreserved human hepatocyte preparations and HepaRG cells","volume":"44","author":"Vermet","year":"2016","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100359_bib36","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/bcp.15544","article-title":"Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours","volume":"89","author":"Chen","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib37","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1002\/cpdd.937","article-title":"Evaluation of the effects of repeat-dose dabrafenib on the single-dose pharmacokinetics of rosuvastatin (OATP1B1\/1B3 substrate) and midazolam (CYP3A4 substrate)","volume":"10","author":"Nebot","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70028","article-title":"Drug-drug interactions of icenticaftor (QBW251) with a 5-probe cytochrome P450 cocktail and oral contraceptives","volume":"17","author":"Huth","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.dmd.2026.100359_bib39","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/cpt.525","article-title":"Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A","volume":"101","author":"Prueksaritanont","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100359_bib40","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/cpt.1073","article-title":"Cytochrome P450 3A induction predicts p-glycoprotein induction; part 1: establishing induction relationships using ascending dose rifampin","volume":"104","author":"Lutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2026.100359_bib41","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/cpt.1072","article-title":"Cytochrome P450 3A induction predicts P-glycoprotein induction; part 2: prediction of decreased substrate exposure after rifabutin or carbamazepine","volume":"104","author":"Lutz","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100359_bib42","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1111\/bcp.15835","article-title":"Effects of nirmatrelvir\/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants","volume":"89","author":"Cox","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1080\/00498250902974229","article-title":"Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes","volume":"39","author":"Floby","year":"2009","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00613427","article-title":"Absorption of digoxin in man after oral and intrasigmoid administration studied by portal vein catheterization","volume":"9","author":"Andersson","year":"1975","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib45","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the Innovation and Quality Induction Working Group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2026.100359_bib46","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/00498254.2016.1222640","article-title":"An exposure-response analysis based on rifampin suggests CYP3A4 induction is driven by AUC: an in vitro investigation","volume":"47","author":"Chang","year":"2017","journal-title":"Xenobiotica"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.xphs.2026.104242","article-title":"Navigating ADME profiling challenges in microphysiological systems: Evaluation of a liver-chip model for clearance prediction","volume":"115","author":"Mettler","year":"2026","journal-title":"J Pharm Sci"},{"issue":"1","key":"10.1016\/j.dmd.2026.100359_bib48","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.124.001497","article-title":"Utilization of a human Liver Tissue Chip for drug-metabolizing enzyme induction studies of perpetrator and victim drugs","volume":"53","author":"Ohri","year":"2025","journal-title":"Drug Metab Dispos"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib49","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1124\/dmd.108.021907","article-title":"Prediction of drug-drug interactions from in vitro induction data: application of the relative induction score approach using cryopreserved human hepatocytes","volume":"36","author":"Fahmi","year":"2008","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.dmd.2026.100359_bib50","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-015-0351-6","article-title":"Predicting drug extraction in the human gut wall: assessing contributions from drug metabolizing enzymes and transporter proteins using preclinical models","volume":"55","author":"Peters","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100359_bib51","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.clpt.2003.10.008","article-title":"Cytochrome P450 3A4 and P-glycoprotein expression in human small intestinal enterocytes and hepatocytes: a comparative analysis in paired tissue specimens","volume":"75","author":"von Richter","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib52","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.apsb.2016.07.012","article-title":"An update on the role of intestinal cytochrome P450 enzymes in drug disposition","volume":"6","author":"Xie","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"2","key":"10.1016\/j.dmd.2026.100359_bib53","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.1365-2125.2002.01615.x","article-title":"Intestinal first pass metabolism of midazolam in liver cirrhosis\u2014effect of grapefruit juice","volume":"54","author":"Andersen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib54","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","article-title":"Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction","volume":"21","author":"Kapetas","year":"2019","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.dmd.2026.100359_bib55","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1208\/s12248-021-00632-7","article-title":"Evidence-based guidelines for drug interaction studies: model-informed time course of intestinal and hepatic CYP3A4 inhibition by clarithromycin","volume":"23","author":"Kapetas","year":"2021","journal-title":"AAPS J"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib56","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/jps.24495","article-title":"Use of a physiologically based pharmacokinetic model for quantitative prediction of drug-drug interactions via CYP3A4 and estimation of the intestinal availability of CYP3A4 substrates","volume":"104","author":"Mano","year":"2015","journal-title":"J Pharm Sci"},{"issue":"9","key":"10.1016\/j.dmd.2026.100359_bib57","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2174\/138920010794328922","article-title":"Predicting drug-drug interactions involving the inhibition of intestinal CYP3A4 and P-glycoprotein","volume":"11","author":"Tachibana","year":"2010","journal-title":"Curr Drug Metab"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006288?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626006288?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:53:09Z","timestamp":1791996789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626006288"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0090955626006288"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100359","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microfluidic liver-chip to predict clinical drug-drug interaction net effects for precipitant drugs with dual CYP3A4 inhibition and induction potential","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100359"}}